Drugs & Targets FDA expands Reblozyl’s indication to first-line treatment of anemia in lower-risk myelodysplastic syndromes September 08, 2023Vol.49 No.33
Drugs & Targets FDA clears AION’s continuous temperature monitoring device and software platform September 08, 2023Vol.49 No.33
Drugs & Targets EC approves Keytruda + trastuzumab + chemo for first-line treatment of GEJ cancer September 08, 2023Vol.49 No.33
Drugs & Targets EMA validates odronextamab application for R/R follicular lymphoma and DLBCL September 08, 2023Vol.49 No.33
Drugs & TargetsFree FDA grants accelerated approval to Talvey for R/R multiple myeloma August 11, 2023Vol.49 No.32
Drugs & TargetsFree FDA approves companion diagnostic to Ayvakit in gastrointestinal stromal tumors August 11, 2023Vol.49 No.32
